Navigation Links
SmartGene, Inc. Enters Collaboration with Virco Lab, Inc. to Enhance HIV Genotyping and Resistance Interpretation Services in US
Date:4/20/2009

RALEIGH, N.C., April 20 /PRNewswire/ -- SmartGene, Inc., a provider of novel services for the management and analysis of genetic data, today announced a marketing and distribution collaboration with Virco Lab, Inc., to help US laboratories manage, analyze, and derive maximum benefit from their HIV sequences. Virco will market SmartGene, Inc.'s secure, Web-based service module, SmartGene(R) HIV, which is a unique, integrated, data management solution encompassing various interpretation algorithms, multiple genetic targets and cumulative resistance reporting.

The SmartGene HIV platform will allow laboratories using both SmartGene, Inc. and Virco services to send an order for interpretation of sequence data by Virco directly out of the SmartGene HIV module and then store the resulting virco(R)TYPE HIV-1 resistance reports within their SmartGene database.

"HIV clinicians and laboratorians understand the importance of longitudinal data to resistance assessment; they value the insight gained from reinterpreting sequences with updated algorithms and comparing results derived from different algorithms; they are interested in analyzing new genetic targets, such as Integrase and Envelope. SmartGene HIV exquisitely meets these needs," said David Ellis, President of SmartGene, Inc. "We have made excellent progress introducing our modules supporting bacterial and fungal identification by sequence analysis. As we expand the deployment of our services for virology in the US, we are delighted to enter this collaboration with Virco, a long-standing market leader for resistance testing and interpretation in the HIV field."

About SmartGene, Inc.

SmartGene, Inc. is the North American subsidiary of SmartGene GmbH, a privately-held company based in Zug, Switzerland, which provides its services worldwide. SmartGene provides web-based suites of functionality to facilitate sequence-based analysis for a variety of clinical, medical research, and veterinary applications. Constant updates to reference data and interpretive algorithms keep SmartGene's customers in step with evolving science and improve the accuracy of sequence interpretation. SmartGene's integrated services increase the speed to result for sequence-based diagnostics and improve workflow in the laboratory. Current modules from SmartGene include Bacteria, Fungi, HIV, HCV, MLST, Influenza, and HLA typing. Future applications will address human genetics as well as food and environmental pathogens. Discover more at www.smartgene.com.


'/>"/>
SOURCE SmartGene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
2. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
3. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
4. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
5. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
6. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
7. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
8. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
9. Elbit Medical Imaging Ltd. Announces that Plaza Centers Has Entered into a Joint Venture Partnership to Develop Residential and Office Projects in Romania
10. Sangui Partnership Enters a New Phase:
11. Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... LOS ANGELES, CA (PRWEB) , ... February 22, ... ... company, today announced that is has acquired Kendall Research Systems, LLC ... of Technology (MIT) that develops neural interface technology for research and clinical applications. ...
(Date:2/22/2017)... DIEGO , Feb. 22, 2017  PrimeVax Immuno-Oncology, ... will be presenting at the Annual Biocom Global Life ... March 2, at 11:15 AM, at the Torrey Pines ... thankful to the organizers at Biocom who have chosen ... international symposium of biotechnology companies, investors, and clinical researchers," ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... the leading medical education provider of women’s health, primary care, and specialty ... Council for Continuing Medical Education (ACCME). ACCME’s Accreditation with Commendation is a ...
(Date:2/22/2017)... ... February 22, 2017 , ... LabRoots , the ... around the world, is pleased to announce the 2nd annual Precision Medicine Virtual ... premier, online-only conference focused on the development and advancements in precision medicine. , ...
Breaking Biology Technology:
(Date:2/8/2017)... (NASDAQ: AWRE ), a leading supplier of biometrics ... and year ended December 31, 2016. Revenue ... to $6.9 million in the same quarter last year. Operating ... compared to $2.6 million in the fourth quarter of 2015. ... million, or $0.02 per diluted share, which compares to $1.8 ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/2/2017)... 2, 2017   TapImmune, Inc. (NASDAQ: ... specializing in the development of innovative peptide and ... cancer and metastatic disease, announced today it has ... of a second clinical lot of TPIV 200, ... alpha. The manufactured vaccine product will be used ...
Breaking Biology News(10 mins):